Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.

ABSTRACT

PURPOSE: The aim of this study was to define the factors that -affect response and post-progression survival of metastatic gastric cancer (MGC) and gastroesophageal junction cancer (GEJ) -patients treated with second-line chemotherapy. METHODS: We retrospectively reviewed the data of 59 patients with MGC or GEJ adenocarcinoma who received second-line treatment. RESULTS: The median age was 54 years old (26-77). Response to second-line treatment was strongly associated with disease control with first-line treatment (p < 0.01). Median progression-free survival (PFS), overall survival (OS) and post-progression survival (PPS) were 3.2 (95% CI  2.63-3.80), 6.5 (95% CI  3.78-9.35) and 2.7 months (95% CI  1.89-3.68), respectively. PFS (r = 0.55, p < 0.01) and PPS (r = 0.89, p < 0.01) were correlated with OS. Response to second-line treatment was independently related to PFS (HR  0.12 95%CI  0.53-0.26, p < 0.001). Having an ECOG 0 performance status (HR  0.42 ; 95%CI  0.21-0.86, p = 0.02) and response to second-line therapy (HR  0.47 ; 95%CI  0.25-0.85, p = 0.01) were independently associated with OS. CONCLUSION: PPS and PFS were correlated with OS after second-line treatment of MGC. Response to second-line treatment prolonged OS by increasing PFS, and having an ECOG 0 PS prolonged OS by increasing PPS.